SCHEMBL1035756

SCHEMBL1035756

O=C(Nc1ccncn1)c1cccc2cnc(-c3cccnc3)nc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 4/20 0.55
CYP2C9 P11712 3/20 0.55
CYP2C19 P33261 3/20 0.55
CYP2D6 P10635 2/20 0.55
CYP3A4 P08684 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
ALDH1A1 P00352 3/20 0.54
POLB P06746 2/20 0.54
ATR Q13535 1/20 0.53
CHRNB2 P17787 1/20 0.53
CHRNB4 P30926 1/20 0.53
CHRNA3 P32297 1/20 0.53
CHRNA4 P43681 1/20 0.53
KMT2A Q03164 3/20 0.49
PPARG P37231 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
NR2E3 Q9Y5X4 1/20 0.49
NCOR2 Q9Y618 1/20 0.49
LMNA P02545 2/20 0.48
IDE P14735 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1035668 0.88 CYP1A2 (0.55) CYP1A2CYP2C9CYP2C19CYP2D6CYP3A4
SCHEMBL1036245 0.87 ATR (0.58) CYP1A2CYP2C9CYP2C19CYP2D6CYP3A4
SCHEMBL1035431 0.84 EGLN1 (0.54) CYP1A2CYP2C9CYP2C19CYP2D6CYP3A4
SCHEMBL1035413 0.84 MPL (0.49) CYP1A2CYP2C9CYP2C19CYP2D6CYP3A4
SCHEMBL1034289 0.80 NPC1 (0.50) CYP1A2CYP2C9CYP2C19CYP2D6CYP3A4
SCHEMBL1034174 0.79 KMO (0.49) CYP1A2CYP2C9CYP2C19CYP2D6CYP3A4
SCHEMBL1033586 0.77 KDM4E (0.56) CYP1A2CYP2C9CYP2D6CYP3A4SMN1; SMN2
SCHEMBL1033047 0.77 CYP11B1 (0.49) CYP1A2CYP2C9CYP2C19CYP2D6CYP3A4
SCHEMBL14082570 0.75 DEGS1 (0.70) SMN1; SMN2ALDH1A1POLBATRCHRNB2
SCHEMBL1031026 0.74 ATR (0.57) CYP1A2CYP2C9CYP2C19CYP2D6CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2273992-B1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2016-05-25 EP disclosed
EP-2273992-B1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2016-05-25 EP disclosed
US-20110046110-A1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2011-02-24 US disclosed
US-20110046110-A1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2011-02-24 US disclosed
US-20110046110-A1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2011-02-24 US disclosed
EP-2273992-A1 QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS Sirtris Pharmaceuticals, Inc. (US) 2011-01-19 EP disclosed
WO-2009134973-A1 QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2009-11-05 WO disclosed
WO-2009134973-A1 QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2009-11-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046110-A1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRT3, SIRT1, SIRT2 CYP1A2 2055/4885CYP2C9 3401/4885CYP2C19 3046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.